● XORTX’s Proprietary Formulation of Oxypurinol – XORLO™ – to Treat Progressive Kidney Disease Associated with Autosomal Dominant Polycystic Kidney Disease (ADPKD)...
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular...
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
NEW YORK and LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused...
Maximizing global leadership of SYFOVRE in geographic atrophy (GA)Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3GFocusing...
Eagle plans to file a new drug application (“NDA”) for EA-114 in 2024 EA-114 is anticipated to meaningfully optimize the...
Castellum Announces the Award of a $3 million Contract to its Specialty Systems, Inc. Subsidiary Castellum, Inc. (NYSE-American: CTM) (“Castellum”)...
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of...
Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back...
Bioventure Bioventure logo Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureAlvotech (NASDAQ:...
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and BioventureREYKJAVIK, Iceland and DUBAI,...
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenous Tecentriq, including certain types of lung,...
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4BERKELEY,...
Cash balance of $17.5 million as at June 30, 2023Revenue of $1.2 million (vs 2022: $0.8 million, an increase of...
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC")...
Minimally invasive device reduces intraocular pressure for adults with open angle glaucomaATLANTA--(BUSINESS WIRE)--Georgia Eye Partners is proud to share that...
Eugene, Oregon--(Newsfile Corp. - August 29, 2023) - Silo Wellness, Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K7A) ("SILO") has confirmed...
NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIALNEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMEDHAMBURG, GERMANY / ACCESSWIRE / August 29, 2023...
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, BC / ACCESSWIRE /...
SAN DIEGO--(BUSINESS WIRE)--$MASI #MasimoCorporation--Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons who purchased...